Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”

Thomas J. Walsh; Brad Moriyama; Scott R. Penzak; Teri E. Klein; Kelly E. Caudle

doi:10.1002/cpt.811

Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”

Thomas J. Walsh, Brad Moriyama, Scott R. Penzak, Teri E. Klein, Kelly E. Caudle

Pharmacotherapy

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English
Pages (from-to)	187
Number of pages	1
Journal	Clinical Pharmacology and Therapeutics
Volume	103
Issue number	2
DOIs	https://doi.org/10.1002/cpt.811
State	Published - Feb 2018

Access to Document

10.1002/cpt.811

Cite this

@article{17d70aba8468474392a711dd76b4e3e5,

title = "Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”",

author = "Walsh, {Thomas J.} and Brad Moriyama and Penzak, {Scott R.} and Klein, {Teri E.} and Caudle, {Kelly E.}",

note = "Funding Information: 1Transplantation – Oncology Infectious Diseases, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA; 2National Institutes of Health (NIH) Clinical Center, Pharmacy Department, Bethesda, Maryland, USA; 3Department of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA; 4Department of Biomedical Data Science, Stanford University, Stanford, California, USA; 5Department of Pharmaceutical Sciences, St. Jude Children{\textquoteright}s Research Hospital, Memphis, Tennessee, USA. Correspondence: TJ Walsh (thw2003@med.cornell.edu)",

year = "2018",

month = feb,

doi = "10.1002/cpt.811",

language = "English",

volume = "103",

pages = "187",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure

T2 - New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”

AU - Walsh, Thomas J.

AU - Moriyama, Brad

AU - Penzak, Scott R.

AU - Klein, Teri E.

AU - Caudle, Kelly E.

N1 - Funding Information: 1Transplantation – Oncology Infectious Diseases, Departments of Medicine, Pediatrics, and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, New York, USA; 2National Institutes of Health (NIH) Clinical Center, Pharmacy Department, Bethesda, Maryland, USA; 3Department of Pharmacotherapy, University of North Texas, System College of Pharmacy, Fort Worth, Texas, USA; 4Department of Biomedical Data Science, Stanford University, Stanford, California, USA; 5Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA. Correspondence: TJ Walsh (thw2003@med.cornell.edu)

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85034115833&partnerID=8YFLogxK

U2 - 10.1002/cpt.811

DO - 10.1002/cpt.811

M3 - Letter

AN - SCOPUS:85034115833

SN - 0009-9236

VL - 103

SP - 187

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 2

ER -

Response to “Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole”

Access to Document

Other files and links

Cite this